The study aimed to conduct a randomized, non-inferiority controlled trial to compare the short- and medium-term efficacy and safety of two antibiotic dosage regimens in cardiac implantable electronic devices (CIED) infections with multidrug-resistant Gram-positive cocci: 1) single-dose therapy with a long-half-life antibiotic (oritavancin) vs. standard 7-14 days of therapy with a short-half-life antibiotic (vancomycin) for CIED surgical incision site or pocket infection; and 2) fractionated therapy with a long-half-life antibiotic (oritavancin) at seven-day intervals compared to standard therapy with a short-half-life antibiotic (vancomycin) fractionated in 2-3 daily doses in cases of lead-related infectious endocarditis.

Start Date01 Jun 2025

Sponsor / Collaborator

Medical University of Silesia

[+1]

NCT05521880

/ TerminatedPhase 4IIT

Anchoring Intermittent Long Acting Antimicrobials to Medication for Opioid Use Disorder Treatment to Facilitate Structured Transitions of Care for People Who Use Drugs Admitted to the Hospital With Invasive Infections

Standard of care for patients with opioid use disorder and complicated infections is discharge to subacute nursing facilities on IV antibiotics until completion of treatment course. We aim to determine the efficacy of an alternative strategy using intermittent outpatient oritavancin therapy dosed weekly combined with initiation and continuation of medication assisted treatment for opioid use disorder for completion of antimicrobial therapy in a 12 week prospective, open-label study. Patients hospitalized for a drug use related infection and thought to need prolonged parenteral antimicrobial therapy will be assessed by a substance use consultant and Infectious Diseases service. If they are not on Medication for Opioid Use Disorder (MOUD), they will be assessed for initiation of MOUD. A collaborative multidisciplinary discharge planning process will be initiated and will involve linkage to care. If they have an infection with a gram positive organism, and are thought to be clinically stable for hospital discharge, they will be assessed for appropriateness for oritavancin and first dose will be administered prior to discharge. They will have an intake into an opioid treatment program where they can access collocated services and will be discharged with linkage to care through a peer recovery coach. They will be assessed in this collocated clinic post discharge for optimization of MOUD and progress of infection and subsequent dose/s of oritavancin will be administered. Patients will be followed for 12 weeks for cure/completion of therapy and MOUD outcomes.

Start Date15 Jul 2024

Sponsor / Collaborator

University of Maryland Baltimore

NCT05599295

/ RecruitingPhase 2

A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin vs SoC for the Treatment of Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

This protocol describes a randomized, open-label study to evaluate the safety and tolerability of single-dose intravenous (IV) oritavancin diphosphate (oritavancin) versus standard of care (SoC) antibiotics for the treatment of pediatric subjects with acute bacterial skin and skin structure infections (ABSSSIs).
This study involves two oritavancin products, ORBACTIV? and KIMYRSATM. Oritavancin is the active drug substance in both ORBACTIV and KIMYRSA. This study protocol distinguishes the differences between ORBACTIV and KIMYRSA by providing product-specific data, and information and guidance for Investigators. "Oritavancin" is used to describe drug product data, and information and guidance that is not specific to ORBACTIV or KIMYRSA (i.e., applies to both).
The study involves pharmacokinetic (PK) sampling and will evaluate clinical outcome assessments. The study was designed to capture adequate data while minimizing the impact to subjects and their caregivers.

Start Date15 Jun 2023

Sponsor / Collaborator

Melinta Therapeutics, Inc.

100 Clinical Results associated with Oritavancin Diphosphate

100 Translational Medicine associated with Oritavancin Diphosphate

100 Patents (Medical) associated with Oritavancin Diphosphate

470

Literatures (Medical) associated with Oritavancin Diphosphate

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Unveiling the effect of chemical degradation on cyclic lipoglycopeptide Oritavancin using Orbitrap mass spectrometry

Article

Author: Gandhi, Gunjan ; Sharma, Nitish ; Paritala, Sree Teja ; Dongare, Jayesh

Oritavancin is the second-generation approved semisynthetic cyclic lipoglycopeptide by the United States Food and Drug Administration (USFDA) for acute bacterial skin and skin-structure infections which serves as a last resort of treatment. Unlike other lipoglycopeptides, the stability behavior of Oritavancin was least explored, which is a prerequisite. The current study endeavors to elucidate the oxidative, hydrolytic, thermal and photolytic stability behavior of Oritavancin by exposing the drug to respective stress conditions. A simple liquid chromatography (LC) method was developed, where significant resolution between Oritavancin and the generated degradation products was achieved. In total 13 degradation products were identified under various stress conditions. Using LC-HRMS, MS/MS studies, the generated degradation products were identified and characterized. The intact mass for DP-2,7,12 was m/z 724.7219(2), DP-6,11, 13 was m/z 796.2672(2), DP-3,10 was m/z 643.6953(2). However isomeric mass as of ORT intact form was seen for DP-4 and unique masses were identified for DP-1,4,8,10 with m/z 725.4293(2), m/z 905.2965(2), m/z 863.2896(2), m/z 904.2890(2) respectively. The mechanistic fragmentation pathway for all the generated DP's were established and the plausible structure for the identified DP's were postulated based on the MS/MS data. According to the findings, Oritavancin is highly susceptible to photolytic, thermal and hydrolytic condition and least susceptible under oxidative condition. The developed reversed-phase high-performance liquid chromatographic (RP-HPLC) method was validated in accordance with ICH guidelines for Oritavancin using C₁₈ analytical reverse-phase column which could be utilised for routine quality control and therapeutic drug monitoring of Oritavancin.

08 Jul 2025·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?

Article

Author: Bongiovanni, Marco ; Turicchi, Giulia

01 Jul 2025·CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

CORR Insights®: Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium?

Article

Author: Webb, Matthew L.

News (Medical) associated with Oritavancin Diphosphate

07 Aug 2025

·pipelinereview.com

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN ® and REZZAYO™. The proposed acquisition will expand CorMedix’s team and commercial platform, and increase the commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO™ (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate). REZZAYO™ is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. The completion of the Phase III study for REZZAYO™ is expected in 1H 2026. “This acquisition is a transformational step in the evolution of CorMedix, providing an attractive revenue base of highly synergistic assets, as well as multiple opportunities to drive future growth. We are excited to acquire Melinta, which enables us to expand our product portfolio in the hospital space while delivering therapies to patients with high unmet need,” said Joseph Todisco, CEO of CorMedix Inc. “I would like to congratulate Christine Ann Miller, Melinta Therapeutics President & CEO, on building a high-performing organization. The combination with Melinta creates a formidable and diversified specialty platform with a deep and experienced team in the hospital acute care and infectious disease arena. This transaction reflects the type of high-impact, cash-flow generating opportunities we are targeting and strengthens our position to further expand, as we strive to create shareholder value through both organic growth and additional acquisitions in the future.” “The synergistic combination of Melinta and CorMedix represents an exciting new chapter in our company’s evolution,” said Christine Ann Miller, President and CEO of Melinta Therapeutics. “Over the past five years, we have built a robust commercial infrastructure with a high-performing team, deep expertise, and relationships within the hospital and acute care ecosystem, while achieving significant revenue growth and sustained profitability. CorMedix recognizes not just our innovative therapies, but the exceptional capabilities of our organization. I’m confident that Melinta’s commercial excellence and proven track record will augment CorMedix’s team and track record of operational execution and success, to create an even stronger platform for future growth.” Strategic and Financial Benefits Terms and Financing Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders of Deerfield Management Company, L.P. (“Deerfield”). The cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing with high quality healthcare focused institutional investors, including Deerfield, the terms of which will be described in a Current Report on Form 8-K to be filed by the Company today. The agreement contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix’s election) for the FDA approval of the expanded indication of REZZAYO™ for prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantation, if this milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO™ U.S. net sales and low-single-digit royalties on MINOCIN ® U.S. net sales. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the ‘HSR Act’). The Company expects the transaction to close as early as September 1, 2025. Full Year Financial Guidance Advisors Moelis & Company LLC is acting as exclusive financial advisor for CorMedix in connection with the acquisition of Melinta and sole placement agent for convertible debt financing. Willkie Farr & Gallagher LLP is acting as legal advisor to CorMedix in connection with the acquisition of Melinta and the convertible debt financing. RBC Capital Markets is acting as a financial advisor to CorMedix in connection with the convertible debt financing. Goodwin Procter LLP is acting as a legal advisor to Moelis & Company LLC for the convertible debt financing. Conference Call and Webcast Information Management will host a conference call and a live webcast today, August 7, 2025, at 8:30 a.m. ET, to discuss the transaction and CorMedix’s second quarter 2025 financial results. The conference call can be accessed by dialing 1-844-676-2922 from the United States or 1-412-634-6840 internationally. The live webcast will be accessible in the “ Presentations & Events ” section of the CorMedix Investor Relations website or using the following Webcast Link . About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath ® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath ® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath ® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com . About Melinta Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: MINOCIN ® (minocycline), REZZAYO™ (rezafungin), VABOMERE ® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), and TOPROL-XL ® (metoprolol succinate). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit www.melinta.com . SOURCE: CorMedix

Drug ApprovalPhase 3AcquisitionLicense out/in

02 Dec 2024

·www.businesswire.com

Melinta Joins NHIA Future of Infusion Advisory Council

ALEXANDRIA, Va. & PARSIPPANY, N.J.--( BUSINESS WIRE )--The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC). FIAC is a strategic advisory group comprised of manufacturing and service companies that are intensely invested in the home and alternate site infusion industry. The group consistently works with the association staff and Board of Directors to address critical issues, challenges, and opportunities facing this growing segment of healthcare. For Melinta, membership in the FIAC provides the opportunity for critical collaboration with the association and other organizations serving patients requiring infusion therapies. This work helps to enhance continuity of care as patients transition out of the hospital. “We’re excited to join FIAC and collaborate with health care professionals on the patient experience both immediately and long-term,” said John Harlow, Chief Commercial Officer at Melinta. “Through our partnership with NHIA, we have built a stronger understanding of the home infusion marketplace and customer needs, helping us address the changing landscape in outpatient infusion. Together, we can make a real difference in patient care – today and tomorrow.” Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on therapeutic areas with unmet needs to make the greatest possible impact on patients. Through collaboration with health care providers, we ensure the patients who need our therapies receive them. “We look forward to building on our long-standing partnership with Melinta through their engagement in FIAC,” said Connie Sullivan, NHIA President and CEO. “By collaborating with industry leaders in this way, we can improve upon the ways we mutually serve the infusion community, which helps more patients lead healthy, independent lives.” About NHIA National Home Infusion Association (NHIA) is a trade association that represents companies accredited to provide medically necessary infusion therapies to patients with acute and chronic health conditions, as well as companies that manufacture and supply infusion related products and services. Infusion therapy involves patient-specific compounded medications, supplies, and a range of pharmacy, nursing, and other clinical services for delivering care to patients in the home or suite setting. About Melinta Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), MINOCIN ® (minocycline) for Injection, ORBACTIV ® (oritavancin), REZZAYO™ (rezafungin for injection), TOPROL-XL ® (metoprolol succinate) and VABOMERE ® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, including their important safety information, visit Melinta.com .

Executive ChangeDrug Approval

23 May 2024

·www.biospace.com

Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris

Publication reaffirms the efficacy of rezafungin for treatment of candidemia and invasive candidiasis (IC) in adult patients across Candida species PARSIPPANY, N.J.--(BUSINESS WIRE)-- Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed ReSTORE phase 3 global clinical trial evaluating REZZAYO® (rezafungin for injection) for the treatment of candidemia and invasive candidiasis (IC) in adults. The data analyses in the article, “Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis,” published in the American Society for Microbiology Antimicrobial Agents and Chemotherapy, demonstrates the efficacy of rezafungin in adult patients across a variety of Candida species. Rates of global cure and mycological eradication at day 14 and all-cause mortality at day 30 were generally comparable between the two treatment groups. The article additionally highlights the approval of the Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints for rezafungin against several Candida species including Candida glabrata, a species increasingly associated with reduced susceptibility to treatment with echinocandins, and Candida auris, a highly resistant pathogen that is associated with life-threating infections. Rezafungin is the only antifungal, based on in vitro data, that has a defined susceptibility breakpoint for C. auris approved by CLSI; the efficacy of rezafungin in treating candidemia or invasive candidiasis caused by this pathogen has not been established in adequate and well-controlled clinical trials. Christine Ann Miller, president and chief executive officer of Melinta Therapeutics, said, "We are delighted with the release of this analysis of data from the ReSTORE Phase 3 trial, which supports the effectiveness and safety of REZZAYO in comparison to caspofungin and are also pleased to see that CLSI approved the REZZAYO susceptibility breakpoints for Candida pathogens, including C. auris, which has been identified as a potential global threat by the CDC and WHO.” She added, "Melinta has been leveraging our expertise in hospital and acute care environments to commercialize REZZAYO, making it available to healthcare providers and their patients affected by candidemia and invasive candidiasis. This effort supports our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses." Melinta holds the exclusive rights to commercialize rezafungin in the U.S. from Mundipharma. About REZZAYO® (rezafungin for injection) REZZAYO (rezafungin for injection) is a novel once weekly echinocandin approved in the United States for the treatment of candidemia and invasive candidiasis in adults. REZZAYO is currently being studied for the prevention of invasive fungal diseases in adults undergoing allogeneic blood and marrow transplantation. INDICATIONS AND USE REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data. REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. IMPORTANT SAFETY INFORMATION Contraindications REZZAYO is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins. Warnings and Precautions Infusion-related Reactions: REZZAYO may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion. Photosensitivity: REZZAYO may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation. Hepatic Adverse Reactions: Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO therapy. Adverse Reactions Most common adverse reactions (incidence ≥ 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. Please see the full Prescribing Information for REZZAYO (rezafungin for injection), available at . About Melinta Therapeutics, LLC Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO® (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit .

Phase 3Drug ApprovalLicense out/inClinical Result

100 Deals associated with Oritavancin Diphosphate

External Link

KEGG	Wiki	ATC	Drug Bank
D05271	Oritavancin Diphosphate	J01XA05	DB04911

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Skin and skin structure infections	United States	Melinta Therapeutics, Inc.	06 Aug 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial Infections	NDA/BLA	Canada	Xediton Pharmaceuticals, Inc.	01 Aug 2024
Abscess	Phase 3	United States	Melinta Therapeutics, Inc.	01 Dec 2010
Cellulitis	Phase 3	United States	Melinta Therapeutics, Inc.	01 Dec 2010
Wound Infection	Phase 3	United States	Melinta Therapeutics, Inc.	01 Dec 2010
Erysipelas	Phase 2	United States	Melinta Therapeutics, Inc.	15 Jun 2023
Erysipelas	Phase 2	Bulgaria	Melinta Therapeutics, Inc.	15 Jun 2023
Erysipelas	Phase 2	Greece	Melinta Therapeutics, Inc.	15 Jun 2023
Erysipelas	Phase 2	Latvia	Melinta Therapeutics, Inc.	15 Jun 2023
Erysipelas	Phase 2	Lithuania	Melinta Therapeutics, Inc.	15 Jun 2023
Erysipelas	Phase 2	Poland	Melinta Therapeutics, Inc.	15 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02925416 (CTgov)	Phase 4	Skin Diseases, Bacterial \| Erysipelas	22	Oritavancin (Oritavancin/Oritavancin)	qupldxakqc = wipaiffpsx wzzlbocqqf (yitthertct, wqoksepuzo - gtorzaatwe) View more	-	01 Feb 2024
				Placebo (D5W)+Oritavancin (Oritavancin/Placebo)	qupldxakqc = wgmjemqrbh wzzlbocqqf (yitthertct, xeaydschlj - disaxuufks) View more
NCT02452918 (CTgov)	Phase 4	Skin and skin structure infections \| Erysipelas \| Cellulitis	17	Oritavancin (Oritavancin 1200 mg Without Concomitant Warfarin Therapy)	grnovgjdiz = pxfwggrkgh sneekokmtf (barazsxogs, frftderrgv - fkqpllruhj) View more	-	20 Dec 2023
				Warfarin+Oritavancin (Oritavancin 1200 mg With Concomitant Warfarin Therapy)	grnovgjdiz = cgzovopwff sneekokmtf (barazsxogs, uogageokmm - zvdxomcmek) View more
NCT01252719 (SOLO I, CTgov)	Phase 3	Abscess \| Cellulitis \| Wound Infection	968	Oritavancin (Single-Dose 1200 mg Oritavancin)	gwisghhlvc = lqlbcgwynj yyosprodpz (yksftngmmv, zqzfvbwszq - ogofbvdjtv) View more	-	01 Aug 2022
				Vancomycin (Vancomycin)	gwisghhlvc = sqvdprzpcf yyosprodpz (yksftngmmv, xayqrmeyhr - oqdohuevmb) View more
NCT01252732 (SOLO II, CTgov)	Phase 3	Abscess \| Cellulitis \| Wound Infection	1,019	Oritavancin (Single-Dose 1200 mg Oritavancin)	eipfzuvmgf = tdcoapyhjk alpcsxnbmn (ntexygxwbh, plidvrmcxu - hpiueaqfss) View more	-	13 Apr 2021
				Vancomycin (Vancomycin)	eipfzuvmgf = gffximcger alpcsxnbmn (ntexygxwbh, eprhoatvwx - keleuvnoqk) View more
NCT03873987 (CTgov)	Phase 1	Skin and skin structure infections \| Erysipelas \| Cellulitis	102	Kimyrsa	mkemiyabrq = csdnvvgpiq zcxkkyiqqt (sarndspedn, hdglbadbvr - qirhsuzfiz)	-	13 Apr 2021
NCT01252719 \| NCT01252732 (SOLO II \| SOLO I, Pubmed) Manual	Phase 3	Skin and skin structure infections	792	Oritavancin	tgwwbypiqg(ofjimigzgg) = xvfvmgxxlh yqxobnejrj (unerhwnbvt ) View more	Positive	19 Jan 2017
				Vancomycin	tgwwbypiqg(ofjimigzgg) = plktoayasx yqxobnejrj (unerhwnbvt ) View more
NCT01252732 (SOLO II, Pubmed \| Clin Infect Dis) Manual	Phase 3	Gram-Positive Bacterial Infections	1,005	oritavancin	mqbftbotgn(dwoyzcmxrq) = mzxvgrfccl cmcutzgiqb (cwleewdhpw ) View more	Non-inferior	15 Jan 2015
				vancomycin	mqbftbotgn(dwoyzcmxrq) = gxbvzdwclg cmcutzgiqb (cwleewdhpw ) View more
NCT01252719 (SOLO I, Pubmed \| N Engl J Med)	Phase 3	Skin Diseases, Bacterial	475	Oritavancin 1200 mg	jcudghmsyy(kxzohoyyxj) = nausea was more common among those treated with oritavancin nxcdfoezjx (eszngiuyzp )	Positive	05 Jun 2014
				Vancomycin
NCT00514527 (SIMPLIFI, Pubmed \| Antimicrob Agents Chemother)	Phase 2	Abscess \| Streptococcal Infections \| Skin and skin structure infections ... View more	302	Daily-dose group	xnzejxxgfu(oypcqretlg) = craohvpfrk nosflchqie (stbwsyvuud ) View more	Positive	01 Jul 2011
				1,200-mg-single-dose group	xnzejxxgfu(oypcqretlg) = ltsnegprcr nosflchqie (stbwsyvuud ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis